Prot #FGCL-3019-091: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Project: Research project

Project Details

StatusActive
Effective start/end date7/16/197/16/22

Funding

  • Worldwide Clinical Trials, Inc. (Prot #FGCL-3019-091)
  • FibroGen, Inc. (Prot #FGCL-3019-091)